Table 1 Baseline characteristics of included patients
Characteristics | Total | Meet-URO Group 1 (Score: 0–3) | Meet-URO Group 2 (Score: 4–5) | Meet-URO Group 3 (Score: 6–8) | p-value |
|---|---|---|---|---|---|
Sample size (n) | 72 | 47 | 17 | 8 | Â |
ccRCC (%) | 72 (100) | 47 (100) | 17 (100) | 8 (100) | NA |
Gender (%) | 0.443 | ||||
 Male | 61 (15.28) | 8 (17.02) | 3 (17.65) | 0 (0.00) |  |
 Female | 11 (84.72) | 39 (82.98) | 14 (82.35) | 8 (100.00) |  |
Age (median [IQR]) | 56.50 (52.00, 66.00) | 56 (51.50, 66.00) | 56.00 (54.00, 63) | 62.00 (53.75, 67.50) | 0.507 |
Nephrectomy (%) | 0.004 | ||||
 Yes | 62 (86.11) | 44 (93.62) | 14 (82.35) | 4 (50.00) |  |
 No | 10 (13.89) | 3 (6.38) | 3 (17.65) | 4 (50.00) |  |
ISUP (%) | 0.248 | ||||
 ISUP < 3 | 18 (25.00) | 14 (29.79) | 4 (23.53) | 0 (0.00) |  |
 ISUP ≥ 3 | 37 (51.39) | 23 (48.94) | 10 (58.82) | 4 (50.00) |  |
 NA | 17 (23.61) | 10 (21.28) | 3 (17.65) | 4 (80.00) |  |
T stage ≥ 3 (%) | 0.337 | ||||
 Yes | 24 (33.33) | 17 (36.17) | 4 (23.53) | 3 (37.50) |  |
 No | 26 (36.11) | 16 (34.04) | 9 (52.94) | 1 (12.50) |  |
 NA | 22 (30.56) | 14 (29.79) | 4 (23.53) | 4 (50.00) |  |
N stage (%) | 0.611 | ||||
 0 | 48 (66.67) | 33 (70.21) | 11 (64.71) | 4 (50.00) |  |
 1 | 11 (15.28) | 5 (10.64) | 4 (23.53) | 2 (25.00) |  |
 Nx | 3 (4.17) | 2 (4.26) | 0 (0.00) | 1 (12.50) |  |
 NA | 10 (13.89) | 7 (14.89) | 2 (11.76) | 1 (12.50) |  |
M stage (%) | |||||
 Synchronous | 39 (54.17) | 29 (61.70) | 8 (47.06) | 2 (25.00) |  |
 Metachronous | 33 (45.83) | 18 (38.30) | 9 (52.94) | 6 (75.00) |  |
IMDC group (%) |  < 0.001 | ||||
 Favorable | 16 (22.22) | 16 (34.04) | 0 (0.00) | 0 (0.00) |  |
 Intermediate | 48 (66.67) | 31 (65.96) | 17 (100.00) | 0 (0.00) |  |
 Poor | 8 (11.11) | 0 (0.00) | 0 (0.00) | 8 (100.00) |  |
Bone metastasis (%) | 0.435 | ||||
 Yes | 13 (18.06) | 3 (6.38) | 8 (47.06) | 2 (25.00) |  |
 No | 59 (81.94) | 44 (93.62) | 9 (52.94) | 6 (75.00) |  |
NLR ≥ 3.2 (%) | 0.579 | ||||
 Yes | 14 (19.44) | 2 (4.26) | 9 (52.94) | 3 (37.50) |  |
 No | 58 (80.56) | 45 (95.74) | 8 (47.06) | 5 (62.50) |  |
Prior treatment (%) | 0.776 | ||||
 TKI | 66 (91.67) | 44 (93.62) | 15 (88.24) | 7 (87.50) |  |
 TKI + IO | 4 (5.55) | 2 (4.26) | 1 (5.88) | 1 (12.50) |  |
 TKI + mTOR | 2 (2.78) | 1 (2.12) | 1 (5.88) | 0 (0.00) |  |
2nd-line treatment (%) |  < 0.001 | ||||
 Yes | 64 (88.89) | 44 (93.62) | 13 (76.47) | 7 (87.50) |  |
 No | 8 (11.11) | 3 (6.38) | 4 (23.53) | 1 (12.50) |  |
Based immunotherapy (%) | 0.643 | ||||
 NIV | 2 (2.78) | 2 (4.26) | 0 (0.00) | 0 (0.00) |  |
 PEM | 7 (9.72) | 4 (8.51) | 2 (11.76) | 1 (12.50) |  |
 SIN | 39 (54.17) | 27 (57.45) | 7 (41.18) | 5 (62.50) |  |
 TIS | 3 (4.17) | 3 (6.38) | 0 (0.00) | 0 (0.00) |  |
 TOR | 21 (29.17) | 11 (23.40) | 8 (47.06) | 2 (25.00) |  |